Combination treatment for advanced ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two targeted drugs for advanced or recurrent ovarian cancer in people who do not have a BRCA gene change. The goal is to see if the combination can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced (stage III or IV) or recurrent ovarian cancer.
- Your tumor does not have a BRCA1 or BRCA2 gene change.
- You have at least one measurable tumor or a high CA-125 level or fluid in the belly.
- You are generally well enough to be up and about (ECOG score 0-2).
- Your blood counts and liver/kidney function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial tests a combination of drugs (adebrelimab, chemotherapy, bevacizumab, and fluzoparib) for ovarian cancer that has returned after a period of remission. It may help by using the immune system and targeted therapy to attack cancer cells.
This trial tests two experimental drugs, AK104 and AK112, for ovarian cancer that has come back after standard platinum chemotherapy. It may be an option if your cancer is a high-grade type and you have had prior treatment.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a combination of three drugs — liposomal irinotecan (a type of chemotherapy), sintilimab (an immunotherapy that helps your immune system fight cancer), and anlotinib (a targeted therapy that blocks blood vessels feeding the tumor) — for women with ovarian clear cell carcinoma that has returned or not responded to standard treatment. The goal is to see if this combination can shrink or control the cancer better than existing options.
This trial tests two drugs together for people with cervical cancer that has returned or spread. The goal is to see if the combination can shrink tumors or slow the disease better than current options.
Hear when a new Ovariancancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.